{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:13:17Z","timestamp":1788592397293,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.numecd.2026.104851","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:19:21Z","timestamp":1782314361000},"page":"104851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"Sining","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Olmastroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-5361","authenticated-orcid":false,"given":"Manuela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2026.104851_bib1","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2026.104851_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104851_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104851_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2026.104851_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11883-024-01248-w","article-title":"Ezetimibe: integrating established use with new evidence - a comprehensive review","volume":"27","author":"Olmastroni","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.numecd.2026.104851_bib6","first-page":"257","article-title":"Bempedoic acid (ETC-1002): a current review","volume":"36","author":"Saeed","year":"2018","journal-title":"Cardiol Clin"},{"issue":"12","key":"10.1016\/j.numecd.2026.104851_bib7","article-title":"Defining the role of bempedoic acid in lowering low-density lipoprotein cholesterol %J","author":"Korzh","year":"2020","journal-title":"J Appl Pharmaceut Sci"},{"key":"10.1016\/j.numecd.2026.104851_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113957","article-title":"Safety of PCSK9 inhibitors","volume":"156","author":"Grzesk","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.numecd.2026.104851_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.numecd.2026.104851_bib10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2026.104851_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.2041-210x.2012.00250.x","article-title":"Review of alternative approaches to calculation of a confidence interval for the odds ratio of a 2 \u00d7 2 contingency table","volume":"4","author":"Ruxton","year":"2013","journal-title":"Methods Ecol Evol"},{"key":"10.1016\/j.numecd.2026.104851_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.numecd.2026.104851_bib13","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1002\/sim.6001","article-title":"Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons","volume":"32","author":"Konig","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.numecd.2026.104851_bib14","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2026.104851_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.numecd.2026.104851_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.numecd.2026.104851_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2026.104851_bib18","series-title":"Which statin has the lowest risk of myalgia?","author":"Pejic","year":"2020"},{"key":"10.1016\/j.numecd.2026.104851_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104851_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MED.0000000000000853","article-title":"Bempedoic acid: a new player for statin-intolerant patients and beyond","volume":"31","author":"Giordano","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.numecd.2026.104851_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2017.12.018","volume":"40","author":"Hong","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.numecd.2026.104851_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.clinthera.2018.04.015","article-title":"Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia","volume":"40","author":"Kim","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.numecd.2026.104851_bib23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104851_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043714","article-title":"Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients","volume":"11","author":"Davis","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2026.104851_bib25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Cholesterol Treatment Trialists","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104851_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13219","article-title":"Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study","volume":"290","author":"Casula","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.numecd.2026.104851_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/FJC.0000000000001397","article-title":"The significance of Statin-associated muscle symptoms and its impact on patient adherence and outcomes","volume":"81","author":"Caturano","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.numecd.2026.104851_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14740338.2019.1615053","article-title":"Muscle and statins: from toxicity to the nocebo effect","volume":"18","author":"Pedro-Botet","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.numecd.2026.104851_bib29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104851_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2015.194","article-title":"The diabetogenic action of statins - mechanisms and clinical implications","volume":"12","author":"Betteridge","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2026.104851_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Electronic address cnoau, cholesterol treatment trialists C. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2026.104851_bib32","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1161\/ATVBAHA.121.316893","article-title":"Statin-related new-onset diabetes appears driven by increased insulin resistance: are there clinical implications?","volume":"41","author":"Brinton","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2026.104851_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1239335","article-title":"Statins and risk of type 2 diabetes: mechanism and clinical implications","volume":"14","author":"Laakso","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2026.104851_bib34","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.scib.2021.02.018","article-title":"Low levels of low-density lipoprotein cholesterol and cognitive decline","volume":"66","author":"Hua","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.numecd.2026.104851_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104851_bib36","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104851_bib37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104851_bib38","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104851_bib39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.numecd.2026.104851_bib40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/eurheartj\/ehx661","article-title":"No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data","volume":"39","author":"Harvey","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104851_bib41","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","article-title":"Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies","volume":"29","author":"Olmastroni","year":"2022","journal-title":"European journal of preventive cardiology"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326003133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326003133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:03:13Z","timestamp":1788591793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326003133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0939475326003133"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104851","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104851"}}